Member Posts > Cardiol Therapeutics' CRD-38 and Its Potential to Improve Energy Utilization in the Failing Heart
One of the major challenges in heart failure (HF) is the inefficient energy utilization caused by mitochondrial dysfunction. Mitochondria generate ATP, the energy currency of cells, and their impairment leads to oxidative stress, reduced cardiac efficiency, and ultimately, worsening HF symptoms. Cardiol Therapeutics' CRD-38, a cannabidiol-based subcutaneous therapy, is being developed to address this crucial issue. By leveraging CBD's anti-inflammatory and antioxidant properties, CRD-38 helps to reduce oxidative stress, preserving mitochondrial function. Additionally, its activation of PPAR-γ promotes mitochondrial biogenesis, leading to improved ATP production and energy utilization in heart cells. Preclinical studies highlight the therapy's ability to enhance mitochondrial respiration, protect cardiomyocytes, and improve overall cardiac output. Given that HFpEF patients often experience metabolic inefficiencies that accelerate disease progression, CRD-38 could fill a critical treatment gap. Cardiol Therapeutics is working toward regulatory approvals, with the goal of bringing this promising therapy into clinical trials.

#CardiolTherapeutics #HeartFailureTreatment #BiotechInvesting #ClinicalTrials #CBDTherapeutics #HeartHealth #MedicalInnovation #PharmaceuticalBreakthroughs #CRD38